MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598681 | Name: Daunomycinone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Daunomycinone is the aglycone of daunomycin.

Chemical Structure

Daunomycinone
Daunomycinone
CAS#21794-55-8

Theoretical Analysis

MedKoo Cat#: 598681

Name: Daunomycinone

CAS#: 21794-55-8

Chemical Formula: C21H18O8

Exact Mass: 398.1002

Molecular Weight: 398.36

Elemental Analysis: C, 63.32; H, 4.55; O, 32.13

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
25mg USD 650.00 2 Weeks
50mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Daunomycinone; Daunomycinon; Daunorubicinone; (+)-Daunomycinone; NSC 109351; NSC-109351; NSC109351; Leukaemomycinone C;
IUPAC/Chemical Name
(8S,10S)-8-acetyl-6,8,10,11-tetrahydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
InChi Key
YOFDHOWPGULAQF-MQJDWESPSA-N
InChi Code
InChI=1S/C21H18O8/c1-8(22)21(28)6-10-13(11(23)7-21)19(26)16-15(18(10)25)17(24)9-4-3-5-12(29-2)14(9)20(16)27/h3-5,11,23,25-26,28H,6-7H2,1-2H3/t11-,21-/m0/s1
SMILES Code
O=C(C1=C2C(O)=C3[C@@H](O)C[C@](O)(C(C)=O)CC3=C1O)C4=CC=CC(OC)=C4C2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Daunorubicinone is an aglycone form of the antitumor antibiotic daunorubicin that has been used as a starting material in the synthesis of anticancer agents.
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 30.0 75.31
DMF 30.0 75.31
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 398.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Prikrylova V, Jizba J, Blumauerova M, Huk J, Sedmera P. Microbial transformation of semisynthetic derivatives of daunomycinone modified in ring A. Folia Microbiol (Praha). 1989;34(5):459-62. PubMed PMID: 2630409. 2: Yoshimoto A, Oki T, Umezawa H. Biosynthesis of daunomycinone from aklavinone and epsilon-rhodomycinone. J Antibiot (Tokyo). 1980 Oct;33(10):1199-201. PubMed PMID: 7451370. 3: Aligiannis N, Pouli N, Marakos P, Skaltsounis AL, Pratsinis H. Synthesis and cytotoxic activity of a new potent daunomycinone derivative. Bioorg Med Chem Lett. 2002 Dec 16;12(24):3505-7. PubMed PMID: 12443763. 4: Prikrylová V, Lipavská H, Jizba JV, Fuska J, Podojil M, Vanĕk Z. Synthesis and biological activity of (7S)-O-epoxyalkyl derivatives of daunomycinone. J Antibiot (Tokyo). 1985 Dec;38(12):1714-8. PubMed PMID: 3841537. 5: Karnetová J, Matĕjů J, Sedmera P, Vokoun J, Vanĕk Z. Microbial transformation of daunomycinone by Streptomyces aureofaciens B-96. J Antibiot (Tokyo). 1976 Nov;29(11):1199-202. PubMed PMID: 825496. 6: Ge P, Wang ZQ, Zhang CN. [Synthesis of the dipeptide derivatives of daunomycinone and adriamycinone]. Yao Xue Xue Bao. 1987 Apr;22(4):254-63. Chinese. PubMed PMID: 3687444. 7: Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, DiMarco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C. Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem. 1975 Jul;18(7):703-7. PubMed PMID: 168385. 8: Perchellet EM, Sperfslage BJ, McIlvain CJ, Aligiannis N, Pouli N, Marakos P, Skaltsounis AL, Perchellet JP. Antileukemic activity of synthetic daunomycinone derivatives bearing modifications in the glycosidic moiety. Anticancer Res. 2001 Nov-Dec;21(6A):3957-67. PubMed PMID: 11911277. 9: Arcamone F, Bargiotii A, Cassinelli G, Redaelli S, Hanessian S, Di Marco A, Casazza AM, Dasdia T, Necco A, Reggiani P, Supino R. Stereocontrolled glycosidation of daunomycinone. Synthesis and biological evaluation of 6-hydroxy-L-arabino analogues of antitumor anthracyclines. J Med Chem. 1976 May;19(5):733-4. PubMed PMID: 1271420. 10: Sturdíková M, Fusková A, Prikrylová V, Podojil M, Fuska J. Cytotoxic and mutagenic in vitro effect of 7-O-epoxyalkyl derivatives of daunomycinone. Part IX. Neoplasma. 1986;33(3):297-305. PubMed PMID: 2426609. 11: Aligiannis N, Pouli N, Marakos P, Mitaku S, Skaltsounis AL, Leonce S, Pierre A, Atassi G. Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl) daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo- hexopyranosyl)daunomycinone. Chem Pharm Bull (Tokyo). 2000 Jan;48(1):150-3. PubMed PMID: 10705494. 12: Nakai K, Takagi Y, Tsuchiya T. Synthesis and antitumor activity of 7-O-[2,6-dideoxy-2-fluoro-5-C-(trifluoromethyl)-alpha-L-talopyranosyl]- daunomycinone and -adriamycinone. Carbohydr Res. 1999 Mar 31;316(1-4):47-57. PubMed PMID: 10420587. 13: Blumauerová M, Pokorný V, Stastná J, Hostálek Z, Vanĕk Z. Improved yields of daunomycinone glycosides in developmental mutants of Streptomyces coeruleorubidus. Folia Microbiol (Praha). 1978;23(4):249-54. PubMed PMID: 689569. 14: Kende AS, Tsay YG, Mills JE. Letter: Total synthesis of (+/-)-daunomycinone and (+/-)-carminomycinone. J Am Chem Soc. 1976 Mar 31;98(7):1967-9. PubMed PMID: 1254856. 15: Takagi Y, Kobayashi N, Chang MS, Lim GJ, Tsuchiya T. Synthesis and antitumor activity of 7-O-(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl) daunomycinone derivatives modified at C-3' or C-4'. Carbohydr Res. 1998 Feb;307(3-4):217-32. PubMed PMID: 9675364. 16: Takagi Y, Kobayashi N, Tsuchiya T, Umezawa S, Takeuchi T, Komuro K, Nosaka C. Syntheses and antitumor activities of 7-O-(6-deoxy-2-O-methyl-alpha-L-talopyranosyl)-daunomycinone and -adriamycinone. J Antibiot (Tokyo). 1989 Aug;42(8):1318-20. PubMed PMID: 2759915. 17: Kende AS, Belletire J, Bentley TJ, Hume E, Airey J. Letter: Regiospecif total synthesis of (plus or minus)-9-deoxy daunomycinone. J Am Chem Soc. 1975 Jul 23;97(15):4425-7. PubMed PMID: 1141604. 18: Kumar N, Seshadri R, Israel M. Adriamycin analogues. Preparation of 7-O-(D-ribofuranosyl)-daunomycinone and -adriamycinone. Carbohydr Res. 1986 Sep 15;153(1):171-80. PubMed PMID: 3779691. 19: Lee WW, Martinez AP, Smith TH, Henry DW. Daunomycinone analogues via the Diels-Alder reaction. Synthesis and chemistry of some 6,11-dihydroxy-5,12-naphthacenediones. J Org Chem. 1976 Jun 25;41(13):2296-303. PubMed PMID: 932859. 20: Takagi Y, Sohtome H, Tsuchiya T, Umezawa S, Takeuchi T. Synthesis of 7-O-[2,6-dideoxy-2-fluoro-4-O-(3-fluorotetrahydropyran-2-yl)- alpha-L-talopyranosyl]daunomycinone. J Antibiot (Tokyo). 1992 Mar;45(3):355-62. PubMed PMID: 1577663.